Angela Golden, FNP, DNP, FAANP
Associate Clinical Professor
Northern Arizona University
Munds Park, AZ
THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING SEPTEMBER 18, 2009. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
For many years now, the U.S. Surgeon General has reported that smoking is the leading cause of preventable death. Although far fewer people smoke in 2009 than in decades past, recent evidence shows that quit rates may be slowing, highlighting the need for more consistent implementation of smoking cessation programs. Formerly viewed as merely a distasteful habit, today tobacco dependence is seen as a chronic disease that should – like any persistent illness – be aggressively treated. Fortunately, there are many nonpharmacologic behavioral interventions and pharmacotherapeutic treatment options that can weaken the bonds of tobacco addiction, allowing smokers to quit and thereby improving their health and well-being.
Nurse practitioners (NPs), frequently the most visible clinicians on the front lines of addressing chronic health care problems, act as pivotal advocates and educators for patients. To be a successful provider and educator for their patients who smoke, NPs in the primary care setting need to be equipped to routinely approach the subject with information about the availability, safety, and efficacy of various smoking cessation resources.
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Identify ways to incorporate routine smoking cessation counseling into every office visit.
Describe comprehensive behavioral and pharmacologic strategies nurse practitioners can use to help patients stop smoking.
Select smoking cessation pharmacotherapy based on safety and efficacy profiles for individual patients.
Dr. Golden has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 0905190.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an educational grant from Pfizer Inc.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, or Pfizer Inc.